Jane Street’s Coherus Oncology CHRS Stock Holding History

Jane Street’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-11,300	Closed	-$37.6K	–	9258
2023 Q4	$37.6K	Sell	11,300 -41,700	-79%	-$112K	﹤0.01%	8831
2023 Q3	$198K	Buy	+53,000	New	+$245K	﹤0.01%	7625
2022 Q4	–	Sell	-15,100	Closed	-$145K	–	9228
2022 Q3	$145K	Sell	15,100 -25,100	-62%	-$254K	﹤0.01%	8419
2022 Q2	$291K	Sell	40,200 -3,100	-7%	-$27K	﹤0.01%	7656
2022 Q1	$559K	Buy	+43,300	New	+$551K	﹤0.01%	7256
2021 Q4	–	Sell	-26,100	Closed	-$419K	–	10123
2021 Q3	$419K	Sell	26,100 -1,600	-6%	-$23.5K	﹤0.01%	7599
2021 Q2	$383K	Buy	27,700 +9,900	+56%	+$140K	﹤0.01%	7740
2021 Q1	$260K	Buy	+17,800	New	+$302K	﹤0.01%	7898

Other funds holding CHRS

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Jane Street's CHRS Position: Q2 2026 in Review

Jane Street reduced its Coherus Oncology (CHRS) stake by 4.5% in Q2 2026, selling an estimated $2.99K and leaving 38,663 shares worth $54.1K. The position accounts for ﹤0.01% of the portfolio, ranked #10896.

Jane Street first reported a position in CHRS in Q2 2017 and has held it in 27 quarters since. The position peaked at $2.08M in Q2 2023. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

Jane Street held 38,663 shares of Coherus Oncology worth $54.1K as of Q2 2026.
Jane Street sold 1,831 Coherus Oncology shares in Q2 2026, an estimated $2.99K.
Coherus Oncology made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10896 holding.
Jane Street first reported a position in Coherus Oncology in Q2 2017 and has held it in 27 quarters since.
Jane Street's Coherus Oncology position peaked at $2.08M in Q2 2023.
147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.